ATAI Life Sciences BV

Eli Lilly & Co. will pursue slightly larger acquisitions, along the lines of its $7.8 billion purchase of Centessa Pharmaceuticals Plc, as it searches for assets in the "white spaces" of science, Chief Executive Officer Dave Ricks said. Lilly, now the world's largest pharmaceutical company, has been on a record spending spree funded by its weight-loss and diabetes shots, and Ricks told Bloomberg that reinvesting in human health is more attractive than buying back shares or issuing dividends. He pointed to infectious disease, women's health and psychiatric conditions as areas of opportunity, noting the company acquired three vaccine-makers for as much as $3.8 billion earlier this year and recently agreed to buy psychedelics firm AtaiBeckley Inc. for about the same price. Lilly has completed about 40 deals so far this year, with a total value of more than $20 billion, the highest ever in a single year according to Bloomberg-compiled data. Ricks said the company favors more mature assets when they address brand new problems, a shift from its historical focus on earlier-stage, cheaper drugs.

Eli Lilly and Company has completed its acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. AtaiBeckley's lead investigational program, BPL-003, targets treatment-resistant depression. The transaction was approved by AtaiBeckley shareholders at a special meeting held prior to closing. Carole Ho, Lilly executive vice president and president of Lilly Neuroscience, said AtaiBeckley's neuroplastogens have the potential to open a new paradigm of treatment with rapid-acting therapeutics designed to move away from chronic dosing. Lilly said it is committed to advancing the pipeline for patients who need more options.

Eli Lilly announced it will acquire clinical-stage biotech AtaiBeckley for about $2.8 billion in cash, excluding potential milestone payments. The deal, announced on July 16, gives Eli Lilly access to BPL-003, an investigational drug for treatment-resistant depression that showed strong phase 2 results. The acquisition strengthens Eli Lilly's neuroscience portfolio, which already includes Alzheimer's drug Kisunla and candidates from its recent $6.3 billion purchase of Centessa Pharmaceuticals. The move is part of a broader acquisition spree to diversify beyond its dominant GLP-1 weight-loss franchise, with recent deals also expanding into pain management, oncology, immunology, and infectious diseases.

Eli Lilly has agreed to acquire psychedelic drugmaker AtaiBeckley for $6.75 per share in upfront cash, valuing the deal at approximately $2.8 billion, plus up to $2.50 per share in contingent value rights tied to clinical and regulatory milestones. In other notable deals this week, Dassault Systèmes is in discussions to acquire drug trial software maker ArisGlobal from Nordic Capital for about $2 billion, though talks are ongoing and may not result in a deal. ABB Ltd. agreed to acquire Rotork for £5.03 per share in cash, a 60% premium to the company's three-month average share price, valuing the company at about £4.1 billion. A consortium led by KKR and Energy Capital Partners raised its takeover proposal for Irish energy distributor DCC to £67.97 per share, valuing the company at £5.81 billion, or approximately $7.86 billion. Stripe and Advent International have reportedly made a joint offer to acquire PayPal for $60.50 per share, in a deal that would value the payments company at more than $53 billion, though PayPal's board views the bid as inadequate. Uber Technologies launched a public takeover offer for Germany's Delivery Hero, valuing the food delivery company at about $14.8 billion in equity value. Kimbell Royalty Partners agreed to acquire oil and gas royalty interests from affiliated sellers for approximately $215.4 million, consisting of $74.9 million in cash and 9.5 million newly issued common units. Zoetis announced an agreement to acquire VitalRADS, a Texas-based provider of veterinary imaging services.

Eli Lilly is channeling the massive cash flow from its GLP-1 weight-loss drugs into building a broader pharmaceutical pipeline, with immunology emerging as a key growth area. Mounjaro and Zepbound accounted for nearly two-thirds of the company's first-quarter 2026 revenues, with year-over-year growth of 125% and 80% respectively. The company recently agreed to purchase Ventyx Biosciences and inked a $2.8 billion deal to buy AtaiBeckley, while its immunology drug Ebglyss saw first-quarter 2026 sales rise 141% year over year. Revenue from key drugs in immunology, oncology, and neuroscience grew 160% in the first quarter, though this success is overshadowed by the sheer size of the GLP-1 business. The strategy aims to diversify ahead of eventual GLP-1 patent expirations.

Eli Lilly and Company has agreed to acquire AtaiBeckley in a cash and contingent value rights deal valued at up to $3.8 billion, putting fresh focus on the stock's valuation. AtaiBeckley's share price surged 33.4% on the announcement and is up 84.75% year to date, with a one-year total shareholder return of 156.27% contrasting with a five-year total shareholder return that remains down 58.57%. The stock last closed at $7.15, above Eli Lilly's $6.75 per share cash offer, and its price-to-book multiple stands at 13.2x, more than five times the US pharmaceuticals industry average of 2.4x and more than double the peer group average of 5.5x. The company recorded a loss of $663.4 million on only $3.5 million of reported revenue and is forecast to remain unprofitable over the next three years, suggesting the market is pricing in substantial future potential for its mental health pipeline and clinical-stage assets.

Biotech stocks surged Thursday, led by CareDx which soared over 35% after Medicare finalized a policy confirming coverage for its transplant surveillance portfolio, including AlloSure Kidney and AlloMap Heart, effective August 30, 2026. AtaiBeckley jumped more than 33% on news it will be acquired by Eli Lilly in a deal valued at up to $3.8 billion, comprising $2.8 billion in upfront cash and up to $1.0 billion in contingent value rights tied to milestones for its depression treatments BPL-003 and VLS-01. Abbott Laboratories gained over 10% after reporting second-quarter net sales of $12.6 billion, a 13% increase, and raising its full-year adjusted earnings per share outlook to a range of $5.45 to $5.60. Apollomics added another 21%, bringing its weekly gain to more than 60%, as its lead candidate Vebreltinib advances in a Phase 2 trial for clear cell sarcoma and the company regained Nasdaq compliance. Virax Biolabs rose 13% after its CEO highlighted a narrowed net loss of $5.0 million, a $3.3 million capital raise, and a supply agreement with Fosun Diagnostics, while Entera Bio climbed over 12% ahead of a planned Phase 3 trial for its oral osteoporosis tablet EB613.

AtaiBeckley shares surged to a four-year high after Eli Lilly agreed to acquire the company for up to $3.8 billion. The stock hit an intraday record of $7.22 before closing at $7.15, up 33.4 percent. Under the deal, AtaiBeckley shareholders will receive $6.75 per share in cash plus up to $2.50 per share in contingent value rights tied to milestones, representing a potential 72 percent premium over Wednesday's close. The transaction, expected to close in the third quarter, aims to expand Eli Lilly's presence in treatment-resistant depression and severe psychiatric disorders. Hedge fund ownership rose to 35 funds holding $125 million in the first quarter, up from 23 funds with $96.47 million in the prior quarter.

Shares of AtaiBeckley surged after Eli Lilly agreed to acquire the mental-health biotech for $6.75 per share in cash, plus up to $2.50 per share in milestone payments. The upfront cash portion is roughly $2.8 billion, and the potential milestone payments could add another $1 billion, bringing the total deal value to about $3.8 billion if all conditions are met. AtaiBeckley’s lead drug, BPL-003, is a synthetic psychedelic nasal spray for treatment-resistant depression that has received Breakthrough Therapy Designation and is in Phase 3 trials. The deal is expected to close in the third quarter, pending shareholder and regulatory approvals.

UnitedHealth shares surged more than 7% in premarket trading after the health insurance giant reported better-than-expected second-quarter results and hiked its full-year earnings outlook. The company posted adjusted earnings of $6.38 per share on revenue of $112.03 billion, exceeding analyst forecasts of $4.90 per share and $110.85 billion, respectively. Taiwan Semiconductor Manufacturing fell 4% despite beating earnings estimates, as it raised full-year capital expenditures to between $60 billion and $64 billion and announced an additional $100 billion investment in Arizona. AtaiBeckley soared 34.5% after Eli Lilly agreed to acquire the psychedelic drugmaker for $2.8 billion, or $6.75 per share in cash, with up to an additional $2.50 per share contingent on milestones. GE Aerospace dropped 4% even after topping second-quarter expectations with adjusted earnings of $2.02 per share on revenue of $12.63 billion and raising its full-year guidance. United Airlines declined more than 3% as softer-than-expected third-quarter guidance of $2.50 to $3.50 per share overshadowed an earnings beat, and the carrier also flagged $6 billion in added fuel costs. J.B. Hunt Transport Services gained nearly 7% after reporting earnings of $1.73 per share, beating estimates by 18 cents, while revenue of $3.5 billion was in line with expectations. AeroVironment rose nearly 2% following an upgrade to outperform at Raymond James, and Rocket Companies added 2% after Morgan Stanley raised its price target to $19.

Shares of psychedelic drug developers are surging premarket after Eli Lilly announced a definitive agreement to acquire AtaiBeckley Inc., validating the sector. AtaiBeckley shares rose 30.8%, Compass Pathways gained 7.4%, and GH Research jumped 18.9%. Lilly will pay $6.75 per share in cash, plus up to $2.50 per share via a Contingent Value Right tied to milestones for lead programs BPL-003 and VLS-01, implying an upfront equity value of about $2.8 billion and additional potential value of roughly $1.0 billion. The deal is expected to close in the third quarter. RBC Capital said GH Research represents the most direct read-through given its lead asset GH001 is nearly identical to AtaiBeckley's BPL-003, both based on 5-MeO-DMT for treatment-resistant depression, and maintained an Outperform rating with a $40 price target.

AtaiBeckley N.V. will be added to the Russell 2000 and Russell 3000 indices effective June 29, a move the company notes is significant given over $12 trillion in assets benchmarked to Russell indexes. Canaccord Genuity subsequently raised its price target on the stock from $15 to $17 on July 7, implying more than 227% upside, while reiterating a Buy rating. The revision followed completion of dosing in the Phase 2 Elumina trial of VLS-01 for treatment-resistant depression, with the company targeting Phase 3 development for major depressive disorder and potential expansion into generalized anxiety disorder. AtaiBeckley is a clinical-stage biopharmaceutical company focused on mental health therapies, with a pipeline that includes BPL-003 in Phase 2 for treatment-resistant depression and alcohol addiction, and RL-007 for cognitive decline from schizophrenia.

AtaiBeckley Inc. has completed patient dosing in its Phase 2b Elumina clinical trial evaluating VLS-01, a DMT buccal film, for treatment-resistant depression. The multi-center, double-blind, placebo-controlled study enrolled 156 participants, with topline results expected in the fourth quarter of 2026. The company plans to advance VLS-01 into Phase 3 development for major depressive disorder, while generalized anxiety disorder remains a potential future indication. Canaccord raised its price target on ATAI to $17 from $15 and maintained a Buy rating, noting the trial remains on track.